Edgar Filing: HEMACARE CORP /CA/ - Form 8-K

HEMACARE CORP /CA/ Form 8-K May 13, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 13, 2004

HEMACARE CORPORATION

(Exact Name of Registrant as Specified in its Charter)

CALIFORNIA

(State or other jurisdiction of incorporation)

000-15223 (Commission File No.)

95-3280412

(IRS Employer Identification No.)

21101 Oxnard Street Woodland Hills, CA 91367

(Address of principal executive offices and Zip Code)

Registrant's telephone number, including area code: (818) 226-1968

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits

Exhibit Number	Description
99.1	Press Release issued by HemaCare, dated May 13, 2004
99.2	Transcript of the presentations given by Judi Irving, CEO, and Robert S. Chilton, CFO, at a conference call conducted by HemaCare Corporation on May 13, 2004

ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On May 13, 2004, HemaCare Corporation issued a press release announcing financial results for the third quarter of 2003. A copy is attached as Exhibit 99.1 to this report and is incorporated herein by reference.

On May 13, 2004, HemaCare Corporation held an investor conference call discussing the financial results for the third quarter of 2003. A transcript of the presentations given by Ms. Judi Irving, CEO, and Robert S. Chilton, CFO, in the call is attached to this report as Exhibit 99.2 and is incorporated herein by reference.

The information in this Current Report on Form 8-K, including

Edgar Filing: HEMACARE CORP /CA/ - Form 8-K

the exhibits, will not be treated as "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into a filing under the Securities Act of 1933, or into another filing under the Exchange Act, unless that filing expressly refers to specific information in this report.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 13, 2004 HEMACARE CORPORATION

/s/ Robert S. Chilton

Robert S. Chilton Chief Financial Officer

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press Release issued by HemaCare, dated May 13, 2004
99.2	Transcript of the presentations given by Judi Irving, CEO, and Robert S. Chilton, CFO, at a conference call conducted by HemaCare Corporation on May 13, 2004